
How the eruption of Mt. Vesuvius did something incredible to one man's brain
How the eruption of Mt. Vesuvius did something incredible to one man's brain
Show Caption
Hide Caption
Erupting volcano struck by lightning as spectators watch in awe
Spectators in Guatemala capture on camera the moment lightning struck Volcan del Fuego as it erupted.
Archeologists have previously discovered human brains preserved in a variety of ways, including drying, freezing and tanning. Some preserved brains even resemble soap.
But now they've found something new: a brain that turned into glass.
In a paper published Thursday in the journal Scientific Reports, archeologist and volcanologists show that the shards of black glass found in the skull of a young man who died when Mount Vesuvius erupted in 79 AD are in fact his vitrified brain.
"This is totally counterintuitive," said Guido Giordano, a volcanologist at the Roma Tre University, a public research university in Rome.
"Under normal conditions, you cannot vitrify any organic tissue unless you drop it to well below zero very quickly. But then when it returns to ambient temperature it reverts," he said.
But after doing extensive testing on the black material, they were able to conclusively prove it was indeed vitrified tissue – the man's brain and parts of his spinal cord had turned into glass.
How did this man's brain turn to glass?
In 79 AD, Italy's Mount Vesuvius erupted, utterly destroying the towns of Pompeii and Herculaneum over the course of two days.
On the first day of the eruption, Pompeii was covered in ash and falling debris, but nearby Herculaneum got only a light dusting with ash.
"The first few hours of the eruption of Vesuvius were scary enough to cause most of the people in Herculaneum to flee and search for rescue by the city harbor", said Giordano. "But during the night the first pyroclastic flow was ejected from the volcano, a turbulent mix of ash, pumice and super hot gasses, and hit Herculaneum."
Most of the people were at the seashore when the first pyroclastic flow arrived, because they were likely waiting for rescue. They died when the roiling cloud of hot ash hit.
But inside the Collegium Augustalium, a young man of about 20 years was lying in his wooden bed. The Collegium, located on the city's main street, was a public building dedicated to the worship of Emperor Augustus.
What happened next, as conjectured by the scientists, is as dreadful as it is fascinating.
The ash cloud burst out of Mount Vesuvius was, at its core hot, heavy and deadly. "It's like a landslide. That material is able to knock down houses," said Giordano.
But at the cloud's edges, things are different. It was a deadly haze of superheated grey ash that billowed through the nearly empty town, reaching temperatures of between 1,000 and 1,100 degrees.
It was similar to the ash cloud from the 2018 eruption of Volcán de Fuego in Guatemala, which killed at least hundreds of people.
"In Herculaneum, this ash cloud engulfed the city, hot enough to kill people and raise the temperature of their bodies to above 500 or 600 degrees Celsius (between 930 and 1,100 degrees Fahrenheit,)" Giordano said.
The young man would have died instantly. But what happened to his brain was remarkable – the only such case ever encountered by archeologists.
Almost as soon as it swept through the town, the cloud dissipated. Modern examples of such clouds can disappear within minute. In Herculaneum, it left only a thin layer of ash on the body and in the room, less than one inch.
The temperatures inside of the ash cloud would have been expected to burn up the body and destroy all soft tissues. But it came and went so rapidly that there wasn't time. Instead, scientists believe, the body very quickly cooled back down to the ambient evening air temperature.
"It needed to have first a rise in temperature well above 510° Celsius (950 degrees Fahrenheit), an event that is very fast and then very fast cooling," he said. This caused his brain to turn into glass during the cooling, locking in its structure.
"Inside the skull there were all these black, shiny fragments," Giordano said. "They look like chips of obsidian, black, shiny and spiky."
Some time later, the next wave of pyroclastic flow reached Herculaneum and the entire town was entombed in as much as 60 feet of ash and debris from the volcano.
While the young man's body was initially excavated several years ago, archeologists weren't sure exactly what was in the skull. By testing fragments of what was found, they were able to prove that it was indeed brain tissue and that it was indeed glass.
How are brains typically found in archeological digs?
Given how delicate they are, preserved brains are not as uncommon as might be expected in the archeological record.
A study published in March of last year by scientists at Oxford university found 4,405 examples of human brains being preserved, some of which were more than 12,000 years old. They included brains from Egyptian and Korean royalty, British and Scandinavian monks, Arctic explorers and a large number of bodies from the Middle Ages that were removed from the largest cemetery in Paris before the French Revolution.
Those scientists found five types of brain preservation:
Dehydration (often in desert climates)
Freezing (Arctic explorers and some freeze-dried mummies, especially in the Andes.)
Tanning (bodies preserved in acidic, tannin-filled bogs)
Saponification (sometimes called "grave wax" this is when the fats in the brain turn to a soap-like clump)
An unknown process, often found as some brain soft tissue preserved among otherwise skeletonized remains, commonly in the presence of clay and iron.
The identification of the young Herculaneum man's brain as having turned to glass adds a new – and vanishingly rare – possibility to the list.
As far as the researchers know, "it's the only time this has occurred," said Giordano,

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
an hour ago
- Newsweek
Woman Gets Notification From Pet Camera—Can't Cope With What Dog Is Doing
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A video of a golden retriever caught in the act of "truly phenomenal" behavior in its owner's absence has gone viral on TikTok. The clip was shared by @seoigolden and has amassed over 510,000 views since it was posted on May 22. The dog in the video is a 2-year-old golden retriever called Seoi, according to the caption shared the post, which is written in French. The video, which features footage from a home security camera, was captured in Arcachon Bay in the southwest of France, according to the location shared with the post. French text overlaid on the video translates to: "One day you receive a notification from your you discover your dog on the table." The video shows the dog initially laying on a dining table in a living room setting, before it is later seen standing on top of it on all four legs. The golden retriever later jumps onto the floor and is seen laying still on its back, with its belly exposed and paws in the air. The dog later pokes its face around near the camera before the clip ends. While the pup may have appeared to be acting sneaky in the viral video, it may have acted the same even in the presence of "watching eyes," according to a January 2020 study. The study, published in Scientific Reports, explained that people are less "likely to carry out risky behavior in general" when they feel they're being watched. However, "dogs, despite being highly sensitive to human eyes, do not show the watching-eye effect," the study said. While it may have seemed like the dog was thriving in the absence of its owner and enjoying having the house to itself, our canine companions have a strong attachment to their human parents. The unique relationship between adult dogs and their owners "bears a remarkable resemblance to an infant attachment bond," explained a May 2013 study published in PLOS One. "Dogs are dependent on human care and their behavior seems specifically geared to engage their owners' care-giving system," the study said. 'Adorable' Viewers on TikTok were amused by the golden retriever's antics in the viral clip. Magali Martin191 said: "He's truly phenomenal," while user9255114689381 said the pup is "adorable." User @ wrote: "He does what he can't do when you're around." Nelara 🇲🇶 noted the dog must have been saying: "you shouldn't have left me...I only do stupid you're not there." Tiphbhc wrote: "Well, it's [the floor is] apparently more comfortable than the sofa." CélineP noted: "He even comes to taunt you in front of the camera." Newsweek has contacted the original poster for comment via TikTok and email. This video has not been independently verified. Stock image: A golden retriever laying on the floor of a home. Stock image: A golden retriever laying on the floor of a home. Getty Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@ with some details about your best friend and they could appear in our Pet of the Week lineup.
Yahoo
2 days ago
- Yahoo
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215), supporting the emerging link between CETP-inhibition and prevention of AD pathology -- -- NewAmsterdam to present results during the AAIC conference in July -- NAARDEN, The Netherlands and MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from prespecified Alzheimer's Disease ('AD') biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722). The pivotal Phase 3 BROADWAY study was primarily designed to evaluate the low-density lipoprotein cholesterol ('LDL-C') lowering efficacy of obicetrapib in adult patients with established atherosclerotic cardiovascular disease ('ASCVD') and/or heterozygous familial hypercholesterolemia ('HeFH'), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. As part of this pivotal registration trial for lowering LDL-C, a pre-specified sub-study was conducted to assess the effect of obicetrapib on plasma biomarkers of AD in both the full study population and in patients carrying the ApoE4 gene. 'These findings strongly support a potential preventive strategy for Alzheimer's disease,' said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. 'In this study obicetrapib, a potent CETP inhibitor, improved the progression of key plasma biomarkers of AD pathology over a 12-month period in patients with ASCVD. These data further differentiate obicetrapib and underscore the critical role CETP inhibition may have in mitigating the risk of AD progression, alongside the significant cardiovascular benefits obicetrapib has shown in our pivotal Phase 3 trials.' The AD sub-study results from BROADWAY build on genetic, Mendelian randomization, and NewAmsterdam's pre-clinical data and data from its Phase 2a clinical proof of concept trial. 'These findings have significant implications for AD prevention, especially for the over 25% of the population that carries one or two ApoE4 risk alleles and who currently lack FDA-approved prevention options,' said Philip Scheltens, professor emeritus at Amsterdam University Medical Center. 'The ability to reduce pathological biomarker progression suggests a potential to alter disease trajectory in this population, thereby delaying or preventing the onset of symptoms. The established safety profile of obicetrapib, demonstrated across multiple large clinical trials, combined with its oral administration, may greatly facilitate clinical implementation.' 'These results are the culmination of over two decades of dedicated scientific research. Approximately two thirds of patients with Alzheimer's disease carry the ApoE4 risk isoform that is associated with a much greater risk of developing AD, and the data shared today support our belief that CETP inhibition and specifically raising small functional HDL particles offers a novel and targeted approach to reducing that risk,' said John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam. 'When viewed alongside the totality of evidence generated to date, including improvements in LDL-C, small LDL particles, Lipoprotein (a), and key biomarkers associated with diabetes and renal function, these novel data on the prevention of AD-associated pathology further strengthen obicetrapib's profile as a uniquely differentiated therapy with the potential to address multiple interrelated drivers of chronic cardiometabolic disease and neurodegeneration.' The Company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference in Toronto at the end of July 2025. Design of the Pivotal Phase 3 BROADWAY Clinical Trial The 52-week, global, pivotal, Phase 3, randomized, double-blind, placebo-controlled multicenter trial evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo as an adjunct to maximally tolerated lipid-lowering therapies in patients with ASCVD and/or HeFH whose LDL-C is not adequately controlled. The trial was conducted at sites in North America, Europe, Asia and Australia. A total of 2,530 patients were randomized 2:1 to receive 10 mg obicetrapib or placebo dosed as a once-daily oral treatment, with or without food for 52 weeks. The mean baseline LDL-C for enrolled patients in the obicetrapib arm was approximately 100 mg/dL despite high intensity statin use reported by nearly 70% of patients during screening. Females comprised approximately 34% of the trial population and the median age of participants at baseline was 65 years. The primary endpoint was LS mean percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days which showed a reduction of 33% with imputation. Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo in ApoB, Lp(a), ApoA1, HDL-C, non-HDL-C, total cholesterol, and triglycerides at day 84, and on LDL-C levels at days 180 and 365. Other exploratory outcome measures included time from randomization until the first confirmed occurrence of MACE in the obicetrapib arm compared to placebo. The trial also evaluated the safety and tolerability profile of obicetrapib. Alzheimer's Sub-Study Trial In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified population of ApoE3/4 or 4/4 carriers. The sub-study included 1727 patients, including 367 ApoE4 carriers. The primary outcome measure was p-tau217 absolute and percent change over 12 months. Additional outcome measures included neurofilament light chain ('NFL'), glial fibrillary acidic protein ('GFAP'), p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215). Design of the Phase 2a Alzheimer's Trial The open-label and single-arm trial was designed to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of obicetrapib 10 mg in early AD patients carrying at least one copy of ApoE4. A total of 13 patients were given 10 mg obicetrapib and followed for 24 weeks. NewAmsterdam observed reductions in the levels of 24- and 27-hydroxycholestrol in both plasma and cerebrospinal fluid. Overall, obicetrapib was observed to be well-tolerated. No serious adverse events ('AEs') were reported, nor were any AEs considered to be related to the study drug. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Forward-Looking Statements Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's business and strategic plans, the Company's commercial opportunity, the therapeutic and curative potential of the Company's product candidate, the Company's clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and business milestones, including potential commercialization; whether topline, initial or preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use of our product candidate, if approved; the potential for varying interpretation of the AD sub-study results; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts; the effects of competition on the Company's future business; and those factors described in the Company's public filings with the Securities and Exchange Commission. Additional risks related to the Company's business include, but are not limited to: uncertainty regarding outcomes of the Company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company's business; intellectual property related claims; the Company's ability to attract and retain qualified personnel; and ability to continue to source the raw materials for the Company's product candidate. If any of these risks materialize or the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company's assessments to change. These forward-looking statements should not be relied upon as representing the Company's assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Yahoo
3 days ago
- Yahoo
Scientists make disturbing discovery in riverbed that could endanger millions: 'An emerging public health concern'
A new study has discovered evidence that the presence of microplastics in river water could influence microbial communities, leading to more pathogens and antimicrobial resistance genes. The research team collected water samples from the Oder River, which flows over 522 miles through Czechia, Germany, and Poland, putting them in sanitized containers and adding pre-drained sediment and microplastic particles. Compared to a control group, which did not contain microplastics, the test samples showed a higher abundance of pathogenic bacteria such as Aeromonas salmonicida, Vibrio spp., Escherichia coli, and Salmonella. The microplastic-contaminated samples also showed higher levels of antibiotic resistance genes, per the study published in Scientific Reports. "The presence of microplastics in [a] water environment and their bioavailability may contribute to, or alter the pattern of, the spreading of pathogens and antimicrobial resistance genes," the researchers stated, adding that this could be due to microbial competition and their use of microplastics to create biofilms, which makes these particles an environmentally favorable niche for some bacteria species. "This represents an emerging public health concern, particularly in the context of the One Health framework, which emphasizes the interconnectedness of human, animal, and environmental health," researchers said. Antimicrobial resistance genes are problematic because they help bacteria resist the drugs meant to treat them. Antimicrobial resistance is one of the top global health threats, according to the World Health Organization, which says it makes infections harder to treat and other medical procedures and treatments, such as surgery and chemotherapy, much riskier. Meanwhile, this is not the first time scientists have sounded the alarm about microplastics, which are small plastic particles that break off of larger plastics as they degrade. These plastics are everywhere, including in water, soil, air, clothing, seafood, and salt. For instance, one study found microplastics in nearly every protein source tested, including chicken, tofu, and beef. While researchers and experts still don't understand the health impacts of microplastics, they've been linked to health problems such as cancer, dementia, and impaired blood flow in the brain. These tiny plastic particles could also be harming some of the world's most important archaeological sites. Researchers in England called attention to this issue following the discovery of microplastics in the soil at two historic sites. While it's difficult to remove microplastics from the environment, it's not impossible. For instance, one group of scientists has discovered a way to rid water of microplastics by using egg whites. How often do you worry about the quality of your drinking water? Never Sometimes Often Always Click your choice to see results and speak your mind. Plus, some cities and countries are tackling plastic pollution, which is the source of microplastics. For one, England and France banned plastic cutlery for most fast food and takeout meals, while Los Angeles has banned Styrofoam takeout containers. You can cut down on your own plastic use at home by investing in reusable items like metal razors and non-plastic sandwich bags. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.